Autoimmune hyperthyroidism and thyroid eye disease: what is the role of pro-oxidants and antioxidants?

References

• Cerqueira C, Knudsen N, Ovesen L, et al. Association of iodine fortification with incident use of antithyroid medication–a Danish Nationwide Study. J Clin Endocrinol Metab 2009;94:2400-5
   PubMed Web of Science ®Google Scholar
• Hegedus L. Treatment of Graves’ hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin North Am 2009;38:355-71
   PubMed Web of Science ®Google Scholar
• Subudhi U, Chainy G. Expression of hepatic antioxidant genes in l-thyroxine-induced hyperthyroid rats: regulation by vitamin E and curcumin. ChemBiol Interact 2010;183:304-16
   PubMed Web of Science ®Google Scholar
• Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. CurrOpin Ophthalmol 2011;22:385-90
   PubMed Web of Science ®Google Scholar
• Bednarek J, Wysocki H, Sowinski J. Peripheral parameters of oxidative stress in patients with infiltrative Graves’ ophthalmopathy treated with corticosteroids. Immunol Lett 2004;93:227-32
   PubMed Web of Science ®Google Scholar
• Mascio P, Murphy ME, Sies H. Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols. Am J ClinNutr 1991;53:194-200
   PubMed Web of Science ®Google Scholar
• Kehrer JP. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993;23:21-48
   PubMed Web of Science ®Google Scholar
• Harman D. Aging and oxidative stress. JIFCC 1998;10:24-7
   Google Scholar
• Komosinska-Vassev K, Olczyk K, Kucharz EJ, et al. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves’ disease during therapy. ClinChimActa 2000;300:107-17
   PubMed Web of Science ®Google Scholar
• Asayama K, Dobashi K, Hayashibe H, et al. Lipid peroxidation and free radical scavengers in thyroid dysfunction in the rat: a possible mechanism of injury to heart and skeletal muscle in hyperthiroidism. Endocrinology 1987;121:2112-18
   PubMed Web of Science ®Google Scholar
• Bustamante J, Guerra L, Bredeston L, et al. Melanin content and hydroperoxide metabolism in human melanoma cells. Exp Cell Res 1991;196:172-6
   PubMed Web of Science ®Google Scholar
• Ahsan H, Ali A, Ali R. Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol 2003;131:398-404
   PubMed Web of Science ®Google Scholar
• Ademoğlu E, Gökkuşu C, Yarman S, et al. The effect of methimazole on the oxidant and antioxidant system in patients with hyperthyroidism. Pharmacol Res 1998;38:93-6
   PubMed Web of Science ®Google Scholar
• Gülnur A, Remise G, Sabiha C, et al. Oxidative damage to Nuclear DNA in Hyperthyroid rat liver: inability of vitamin c to prevent the damage. J Toxicol Environ Health A 2004;67:413-20
   PubMed Web of Science ®Google Scholar
• Cross AR, Jones OTG. Enzymic mechanisms of superoxide production. Biochim Biophys Acta 1991;1057:281-98
   PubMed Web of Science ®Google Scholar
• Dupuy C, Virion A, Ohayon R, et al. Mechanism of hydrogen peroxide formation catalyzed by NADPH oxidase in thyroid plasma membrane. J BiolChem 1991;266:3739-43
   PubMed Web of Science ®Google Scholar
• De Zwart LL, Meerman JHN, Commandeur JNM, et al. Biomarkers of free radical damage applications in experimental animals and in humans. Free RadicBiol Med 1999;26:202-26
   PubMed Web of Science ®Google Scholar
• Adali M, Inal-Erden M, Akalin A, et al. Effects of propylthiouracil, propranolol, and vitamin E on lipid peroxidation and antioxidant status in hyperthyroid patients. Clin Biochem 1999;32:367
   Web of Science ®Google Scholar
• Seven A, Seymen O, Hatemi S, et al. Lipid peroxidation and vitamin E supplementation in experimental hyperthyroidism. Clin Chem 1996;42:1118-19
   PubMed Web of Science ®Google Scholar
• Seymen O, Seven A, Hatemi S, et al. Lipid peroxidation in experimental hyperthyroidism: effects of iron supplementation. Med Sci Res 1995;23:695-6
   Google Scholar
• Venditti P, Di Meo S, De Leo T. Effect of thyroid state on characteristics determining the susceptibility to oxidative stress of mitochondrial fractions from rat liver. Cell Physiol Biochem 1996;6:283-95
   Google Scholar
• Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf) 2013;78:155-64
   PubMed Web of Science ®Google Scholar
• Howie AF, Arthur JR, Nicol F, et al. Identification of a 57-kilodalton selenoproteins in human thyrocytes as thioredoxin reductase and evidence that its expression is regulated through the calcium-phosphoinositol signaling pathway. J Clin Endocrinol Metab 1998;83:2052-8
   PubMed Web of Science ®Google Scholar
• Abalovich M, Llesuy S, Gutierrez S, et al. Peripheral parameters of oxidative stress in Graves’ disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol (Oxf) 2003;59:321-7
   PubMed Web of Science ®Google Scholar
• Vadhanavikit S, Ganther HE. Selenium deficiency and decreased coenzyme Q levels. Mol Aspects Med 1994;15:103-7
   Web of Science ®Google Scholar
• Guerra LN, Moiguer S, Karner M, et al. Antioxidants in the treatment of Graves’ disease. IUBMB Life 2001;51:105-9
   PubMed Web of Science ®Google Scholar
• Duntas LH. Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab 2010;95:5180-8
   PubMed Web of Science ®Google Scholar
• Vrca VB, Skreb F, Cepelak I, et al. Supplementation with antioxidants in the treatment of Graves’ disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta 2004;341:55-63
   PubMed Web of Science ®Google Scholar
• Gartner R, Gasnier BC, Dietrich JW, et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab 2002;87:1687-91
   PubMed Web of Science ®Google Scholar
• Gartner R, Gasnier BC. Selenium in the treatment of autoimmune thyroiditis. Biofactors 2003;19:165-70
   PubMed Web of Science ®Google Scholar
• Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol 2003;148:389-93
   PubMed Web of Science ®Google Scholar
• Turker O, Kumanlioglu K, Karapolat I, et al. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol 2006;190:151-6
   PubMed Web of Science ®Google Scholar
• Mazokopakis EE, Papadakis JA, Papadomanolaki MG, et al. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto’s thyroiditis. Thyroid 2007;17:609-12
   PubMedGoogle Scholar
• Nacamulli D, Mian C, Petricca D, et al. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol (Oxf) 2010;73:535-9
   PubMed Web of Science ®Google Scholar
• Karanikas G, Schuetz M, Kontur S, et al. No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid 2008;18:7-12
   PubMed Web of Science ®Google Scholar
• Penglase S, Hamre K, Ellingsen S. Selenium prevents downregulation of antioxidant selenoprotein genes by methyl mercury. Free Radic Biol Med 2014;75:95-104
   PubMed Web of Science ®Google Scholar
• Vrca VB, Mayer L, Skreb F, et al. Antioxidant supplementation and serum lipids in patients with Graves’ disease: effect on LDL-cholesterol. Acta Pharm 2012;62:115-22
   PubMed Web of Science ®Google Scholar
• Guerra LN, Ríos de Molina Mdel C, Miler EA, et al. Antioxidants and methimazole in the treatment of Graves’ disease: effect on urinary malondialdehyde levels. Clin Chim Acta 2005;352:115-20
   PubMed Web of Science ®Google Scholar
• Bacic-Vrca V, Skreb F, Cepelak I, et al. The effect of antioxidant supplementation on superoxide dismutase activity, Cu and Zn levels, and total antioxidant status in erythrocytes of patients with Graves’ disease. Clin Chem Lab Med 2005;43:383-8
   PubMed Web of Science ®Google Scholar
• Gotoh N, Niki E. Rates of interactions of superoxide with vitamin E, vitamin C and related compounds as measured by chemiluminescence. Biochem Biophys Acta 1992;1115:201-7
   PubMed Web of Science ®Google Scholar
• Mohamadin AM, Hammad LN, El-Bab MF, et al. Attenuation of oxidative stress in plasma and tissues of rats with experimentally induced hyperthyroidism by caffeic acid phenyl ethyl ester. Basic Clin Pharmacol Toxicol 2007;100:84-90
   PubMed Web of Science ®Google Scholar
• Zimmermann MB. Interactions of Vitamin A and iodine deficiencies: effects on the pituitary-thyroid axis. Int J VitamNutr Res 2007;77:236-40
   PubMed Web of Science ®Google Scholar
• Frei B, Stocker R, England L, et al. Ascorbate: the most effective antioxidant in human blood plasma. Adv Exp Med Biol 1990;264:155-63
   PubMedGoogle Scholar
• Ibrahim W, Tousson E, El-Masry T, et al. The effect of folic acid as an antioxidant on the hypothalamic monoamines in experimentally induced hypothyroid rat. Toxicol Ind Health 2011;28:253-61
   PubMed Web of Science ®Google Scholar
• Bartalena L, Tanda ML, Piantanida E, et al. Oxidative stress and Graves’ ophthalmopathy: in vitro studies and therapeutic implications. Biofactors 2003;19:155-63
   PubMed Web of Science ®Google Scholar
• Bouzas EA, Karadimas P, Mastorakos G, et al. Antioxidant agents in the treatment of Graves’ ophthalmopathy. Am J Ophthalmol 2000;129:618-22
   PubMed Web of Science ®Google Scholar
• Kawada J, Shirakawa Y, Yoshimura Y, et al. Thyroid xanthine oxidase and its role in thyroid iodine metabolism in the rat: difference between effects of allopurinol and tungstate. J Endocrinol 1982;95:117-24
   PubMed Web of Science ®Google Scholar
• Conney AH, Lysz T, Ferraro T, et al. Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin. Adv Enzyme Regul 1991;31:385-96
   PubMedGoogle Scholar
• Grune T, Jung T, Merker K, et al. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid and ‘aggresomes’ during oxidative stress, aging and disease. Int J Biochem Cell Biol 2004;36:2519-30
   PubMed Web of Science ®Google Scholar
• Brzezińska-Slebodzińska E. Fever induced oxidative stress: the effect on thyroid status at the 5’-monodeionidase activity, protective role of selenium and vitamin E. J PhysiolPharmacol 2001;52:275-84
   Google Scholar
• Kazim M, Goldberg RA, Smith TJ. Insights into the pathogenesis of thyroid associated orbitopathy: evolving rationale for therapy. Arch Ophthalml 2002;120:380-6
   PubMedGoogle Scholar
• Kashkouli MB, Kaghazkanani R, Heidari I, et al. Bilateral versus unilateral thyroid eye disease. Indian J Ophthalmol 2011;59:363-6
   PubMed Web of Science ®Google Scholar
• Manso PG, Furlanetto RP, Wolosker AM, et al. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves’ hyperthyroidism. Thyroid 1998;8:49-52
   PubMed Web of Science ®Google Scholar
• Kashkouli MB. Beyond a typical thyroid eye disease. Middle East Afr J Ophthalmol 2013;20:185-6
   PubMedGoogle Scholar
• Kashkouli MB, Pakdel F, Astaraki A, et al. Quality of life in patients with thyroid eye disease. J Ophthalmic Vis Res 2009;4:164-8
   PubMedGoogle Scholar
• Kashkouli MB, Heidari I, Pakdel F, et al. Change in quality of life after medical and surgical treatment of graves’ ophthalmopathy. Middle East Afr J Ophthalmol 2011;18:42-7
   PubMedGoogle Scholar
• Sergott RC, Glaser JS. Grave’s ophthalmopathy: a clinical and immunologic review. Surv Ophthalmol 1981;26:1-21
   PubMed Web of Science ®Google Scholar
• Glaser JS. Grave’s ophthalmopathy. Arch Ophthalmol 1984;102:1448-9
   PubMedGoogle Scholar
• Char DR. Thyroid Eye Disease. 3rd edition. Mass: Butterworth-Heineman; Boston: 1997. pp. 113-42
   Google Scholar
• Kashkouli MB, Pakdel F, Kiavash V, et al. Hyperthyroid vs hypothyroid eye disease: the same severity and activity. Eye (Lond) 2011;25:1442-6
   PubMed Web of Science ®Google Scholar
• Smith TJ. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 2002;12:197-203
   PubMed Web of Science ®Google Scholar
• Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T-cell chemoattractant expression in fibroblasts from patients with Grave’s disease is mediated through the insulin-like growth factor 1 receptor pathway. J Immunol 2003;170:6348-54
   PubMed Web of Science ®Google Scholar
• Hwang CJ, Afifiyan N, Sand D, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40:CD154 Hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci 2009;50:2262-8
   PubMed Web of Science ®Google Scholar
• McKenzie JM, Zakarija M, Sato A. Humoral immunity in Grave’s disease. Clin Endocrinol Metab 1978;7:31-45
   PubMedGoogle Scholar
• Burch HB, Wartofsky L. Grave’s ophthalmopathy: current concepts regarding pathogenesis and management. Endocr rev 1993;14:747-93
   PubMed Web of Science ®Google Scholar
• Kaur A, Pandey S, Kumar S, et al. Oxidative stress profile in Grave’s ophthalmopathy in Indian patients. Orbit 2010;29:97-101
   PubMedGoogle Scholar
• Lu R, Wang P, Wartofsky L, et al. Oxygen free radicals in interleukin-1β-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Grave’s ophthalmopathy patients. Thyroid 1999;9:297-303
   PubMed Web of Science ®Google Scholar
• Hondur A, Konuk O, Dincel AS, et al. Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves’ ophthalmopathy. Curr Eye Res 2008;33:421-7
   PubMed Web of Science ®Google Scholar
• Kashkouli MB, Jam S, Sabzvari D, et al. Thyroid-associated ophthalmopathy in Iranian patients. Acta Med Iran 2011;49:612-18
   PubMedGoogle Scholar
• Hegediüs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves’ ophthalmopathy. J Endocrinol Invest 2004;27:265-71
   PubMed Web of Science ®Google Scholar
• Burch HB, Lahiri S, Bahn RS, et al. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy. Exp Eye Res 1997;65:311-16
   PubMed Web of Science ®Google Scholar
• Desmouliere A, Guoxiong X, Tuchweber B. Effect of Pentoxifylline on early proliferation and early phenotypic modulation of fibrogenic cells in twotat models of liver fibrosis and on cultured hepatic stellate cells. J Hepatol 1999;30:621-31
   PubMed Web of Science ®Google Scholar
• Finamor FE, Martins JR, Nakanami D, et al. Pentoxifylline [PTX] – an alternative treatment in Graves’ ophthalmopathy [inactive phase]: assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial. Eur J Ophthalmol 2004;14:277-83
   Web of Science ®Google Scholar
• Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J Nutr Biochem 2007;18:427-42
   PubMed Web of Science ®Google Scholar
• Woodman OL, Chan E. Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 2004;31:786-90
   PubMed Web of Science ®Google Scholar
• Yoon JS, Lee HJ, Choi SH, et al. Quercetin inhibits IL-1β-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Grave’s orbitopathy. PLoS One 2011;6:e26261
   PubMed Web of Science ®Google Scholar
• Yoon JS, Chae MK, Jang SY, et al. Antifibrotic effects of Quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Grave’s orbitopathy. Invest Ophthalmol Vis Sci 2012;53:5921-9
   PubMed Web of Science ®Google Scholar
• Lisi S, Botta R, Lemmi M, et al. Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid. J Endocrinol Invest 2011;34:521-7
   PubMed Web of Science ®Google Scholar
• Rayman MP. The importance of selenium to human health. Lancet 2000;356:233-41
   PubMed Web of Science ®Google Scholar
• Dehina NE, Minich W, Behrends T, et al. Circulating selenoprotein P concentrationsare decreased in patients with Graves’ disease and correlate inversely to severity of orbitopathy. Acta Med Port 2009;22:1
   Google Scholar
• Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Grave’s orbitopathy. N Engl J Med 2011;364:1920-31
   PubMed Web of Science ®Google Scholar